DK1007638T3 - KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf - Google Patents

KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf

Info

Publication number
DK1007638T3
DK1007638T3 DK98932877T DK98932877T DK1007638T3 DK 1007638 T3 DK1007638 T3 DK 1007638T3 DK 98932877 T DK98932877 T DK 98932877T DK 98932877 T DK98932877 T DK 98932877T DK 1007638 T3 DK1007638 T3 DK 1007638T3
Authority
DK
Denmark
Prior art keywords
kcnq2
proteins
kcnq3
potassium channels
disease
Prior art date
Application number
DK98932877T
Other languages
Danish (da)
English (en)
Inventor
Steven Dworetzky
Valentin K Gribkoff
Wen-Pin Yang
Michael A Blanar
Paul C Levesque
Michael G Neubauer
Wayne A Little
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21998937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1007638(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1007638T3 publication Critical patent/DK1007638T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK98932877T 1997-08-12 1998-06-26 KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf DK1007638T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5559997P 1997-08-12 1997-08-12
PCT/US1998/013276 WO1999007832A1 (fr) 1997-08-12 1998-06-26 Canaux potassium de kcnq et methodes permettant de les moduler

Publications (1)

Publication Number Publication Date
DK1007638T3 true DK1007638T3 (da) 2007-05-21

Family

ID=21998937

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98932877T DK1007638T3 (da) 1997-08-12 1998-06-26 KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf

Country Status (10)

Country Link
US (4) US6403360B1 (fr)
EP (1) EP1007638B1 (fr)
JP (1) JP2001512673A (fr)
AT (1) ATE356200T1 (fr)
AU (1) AU731087B2 (fr)
CA (1) CA2300985A1 (fr)
DE (1) DE69837267T2 (fr)
DK (1) DK1007638T3 (fr)
ES (1) ES2281129T3 (fr)
WO (1) WO1999007832A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1007638T3 (da) * 1997-08-12 2007-05-21 Bristol Myers Squibb Co KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf
CA2307316C (fr) * 1997-10-24 2010-12-21 University Of Utah Research Foundation Kncq2 et kncq3, genes du canal potassium ayant subi une mutation dans des convulsions neonatales familiales benignes (bfnc) et d'autres epilepsies
WO2000061606A1 (fr) * 1999-04-14 2000-10-19 Merck & Co., Inc. Nouveau canal potassique humain potentiel-dependant
US6649371B1 (en) 1999-06-11 2003-11-18 Neurosearch A/S Potassium channel KCNQ5 and sequences encoding the same
ATE374212T1 (de) * 1999-06-11 2007-10-15 Neurosearch As Neue kalium-kanäle und dafür kodierende gene
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
DE10013732A1 (de) * 2000-03-21 2001-09-27 Aventis Pharma Gmbh Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems
US7049137B2 (en) * 2000-03-21 2006-05-23 Icagen, Inc. KCNQ5, a novel potassium channel
US6617131B2 (en) 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
EP1272634A1 (fr) * 2000-04-03 2003-01-08 Lexicon Genetics Incorporated Proteine humaine du canal ionique et polynucleotides la codant
WO2001092526A1 (fr) * 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Kcnq5, canal potassium humain, procedes et compositions de ce dernier
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
MXPA03007397A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
UA114592C2 (uk) * 2010-09-28 2017-07-10 Ноно Інк. Пептид nd2 та спосіб лікування неврологічного захворювання
FR3029113A1 (fr) * 2014-12-02 2016-06-03 Univ Paris-Sud Composes pour le traitement des maladies mitochondriales
WO2021178769A1 (fr) * 2020-03-06 2021-09-10 Ionis Pharmaceuticals, Inc. Composés et méthodes de modulation de kcnq2
WO2025198930A1 (fr) * 2024-03-18 2025-09-25 Humanwell Pharmacuetical Us, Inc. Petites molécules en tant qu'activateurs de canaux kcnq2/3 (kv7.2/3) et leur utilisation médicale

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09191882A (ja) 1996-01-16 1997-07-29 Japan Tobacco Inc ヒト新規k+チャネル蛋白質をコードするdnaおよびその断片
DK1007638T3 (da) * 1997-08-12 2007-05-21 Bristol Myers Squibb Co KCNQ-kaliumkanaler og fremgangsmåde til modulering deraf
CA2307316C (fr) * 1997-10-24 2010-12-21 University Of Utah Research Foundation Kncq2 et kncq3, genes du canal potassium ayant subi une mutation dans des convulsions neonatales familiales benignes (bfnc) et d'autres epilepsies

Also Published As

Publication number Publication date
EP1007638B1 (fr) 2007-03-07
US20020168724A1 (en) 2002-11-14
WO1999007832A1 (fr) 1999-02-18
ATE356200T1 (de) 2007-03-15
US7041496B2 (en) 2006-05-09
US6403360B1 (en) 2002-06-11
US7262289B2 (en) 2007-08-28
AU8266598A (en) 1999-03-01
CA2300985A1 (fr) 1999-02-18
EP1007638A4 (fr) 2004-12-29
EP1007638A1 (fr) 2000-06-14
AU731087B2 (en) 2001-03-22
DE69837267T2 (de) 2007-10-31
US20070148692A1 (en) 2007-06-28
US7482431B2 (en) 2009-01-27
ES2281129T3 (es) 2007-09-16
US20030044912A1 (en) 2003-03-06
DE69837267D1 (de) 2007-04-19
JP2001512673A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
EP1007638A4 (fr) Canaux potassium de kcnq et methodes permettant de les moduler
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
DE69637256D1 (de) Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
DE69841653D1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
NO970042D0 (no) 2-£(Dihydro)pyrazolyl-3'-oksymetylen|-anilider, fremgangsmåte til fremstilling og anvendelse derav
WO2004058704A8 (fr) Quinazolinones comme modulateurs de canaux potassiques
IL152663A0 (en) Novel multicyclic compounds and the use thereof
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
WO2001001970A3 (fr) Nouvelles utilisations des agents d'ouverture du canal potassique
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
WO2002076494A3 (fr) UTILISATION DE CYTOKINES DE LA SUPERFAMILLE TGF-β POUR LE TRAITEMENT ET LE DIAGNOSTIC DE TROUBLES DE LA PEAU
ATE299179T1 (de) Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung
WO2001031008A3 (fr) Gene fgf-20 humain et produits d'expression genique
EA200001246A1 (ru) Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот
TR199802019T2 (xx) Terap�tik amidleri stereoselektif olarak haz�rlamak i�in enzimatik y�ntem.
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
BR9704615A (pt) formononetina de metal alcalino e processo de estimulação micorrizal
WO2003040320A3 (fr) Modulation par composes antisens de l'expression de la proteine 2 mediatrice de reaction de collapsine humaine (crmp)
EP1191096A4 (fr) Nouvelle proteine et son adn
WO2005002573A3 (fr) Methodes d'utilisation de modulateurs de tyrosine kinase 2 riche en proline
ATE391915T1 (de) Verwendung des proteins grf-1 zur auswahl von molekülen
DE59808160D1 (de) Zusammensetzung zur behandlung von gegerbtem leder, sowie ihre herstellung
DZ2783A1 (fr) Procédé pour obtenir de l'érythropoïetine humaine recombinante et l'érythropoïetine ainsi obtenue.